EMA Confirms Latest Update on Marketing Authorization, Including Label Expansion for Pharma&Pegasys in Myeloproliferative Neoplasms
Pegasys Marketing Authorization Renewal and Hematologic Malignancy Label Expansion
The European Medicines Agency (EMA) has finalized the validity of the European Marketing Authorization (MA) for pharmaand GmbH's Pegasys (peginterferon alfa-2a) and updated its latest product information. Pegasys, widely used as a standard treatment for chronic Hepatitis B and C, has successfully restructured its commercial lifecycle. Following the transfer of rights and licenses from the original developer Roche (Roche, ROG), it recently received official approval from the European Commission (EC) for rare chronic myeloproliferative neoplasm (MPN) indications, such as polycythemia vera (PV) and essential thrombocythemia (ET).
Clinical Value of Immunomodulatory Mechanism and Formulation Technology
Pegasys is a long-acting pegylated biopharmaceutical that significantly reduces systemic clearance by conjugating a 40kDa branched polyethylene glycol (PEG) to a recombinant interferon molecule. It demonstrates a disease-modifying effect by inhibiting the abnormal proliferation of bone marrow hematopoietic stem cell clones and substantially reducing the burden of mutant alleles (such as JAK2V617F). Compared to existing short-acting formulations, it maintains stable blood concentrations, inducing excellent hematologic response rates with only once-weekly subcutaneous administration, thereby drastically improving patient compliance.
Lifecycle Extension Strategy through Indication Expansion of a Legacy Blockbuster
This authorization renewal and label expansion are the results of passing regulatory efficacy and safety verification based on large-scale clinical consortium data (MPD-RC Phase 2 and MPD-RC Phase 3 trials). In a situation where the Hepatitis C market has rapidly shrunk due to the emergence of direct-acting antivirals (DAAs) like Gilead's Sovaldi, the company succeeded in incorporating the myeloproliferative neoplasm treatment area—which previously remained as off-label prescribing—into the official on-label system. This is evaluated as a representative model of lifecycle management, repositioning a patent-expired drug into a specialized treatment for rare hematologic malignancies to convert it into a stable cash cow.
Competitive Landscape in the 4 Trillion KRW Myeloproliferative Neoplasm Market
In the global market for polycythemia vera and essential thrombocythemia, currently valued at approximately $3 billion (approx. 4 trillion KRW), Pegasys is competing directly with PharmaEssentia's Besremi (ropeginterferon alfa-2b), Novartis's Jakafi (ruxolinitib), and the standard cytotoxic agent Hydroxyurea. Having secured decades of accumulated long-term safety data and a robust supply chain across Europe, Pegasys is accelerating both the defense of its prescription market share in 1st and 2nd-line treatment markets and the expansion of reimbursement coverage, following the acquisition of its official label from European regulatory authorities.
This latest EMA marketing authorization renewal and indication label expansion prove the complete re-transition of the interferon market, which had been declining since the emergence of Hepatitis C DAAs, into the specialized $3 billion myeloproliferative neoplasm (MPN) sector. While competitor PharmaEssentia's Besremi is growing rapidly as a high-priced monotherapy in the US and European markets, pharmaand has solidified its European on-label status using MPD-RC Phase 3 clinical data, lowering the barriers to reimbursement entry. As it has demonstrated the effect of reducing JAK2 alleles compared to the existing 1st-line treatment Hydroxyurea, it is expected to maintain a solid, exclusive prescribing position within the hematologic malignancy field.
Source: EMA (ema)